Cipla Q2FY25 Highlights - Umang Vohra, MD & CEO, Cipla - “ We are 89, we have a very strong legacy and we are constantly building for the future. Cipla is an institution, and we will continue to provide high quality medicines for patients across the world. Part of what institutions also do is to leave the world a better place. We continue to create the right set of environmental metrics, to make sure that our planet is better for the children that follow, and also to make sure that we create an

Gaining significant influence in the Indian pharmaceutical scene of the 1960s, we now meet Cipla in the 70s. By this point, the company has introduced over 30 APIs*. It has also expanded its horizons into new areas, including manufacturing and pioneering more effective drug delivery methods. Approaching its golden jubilee in 1985, Cipla, under the leadership of Dr. Y.K. Hamied committed itself to a future defined by innovation. By prioritising manufacturing, research and development, the company

Umang Vohra on Cipla Q4 & Full Year FY23 Results: Strong operating quarter - highest ever revenue with EBITDA crossing INR 5,000 Cr for the first time. Strong momentum across all markets especially One-India business recording double-digit growth and US business posting highest ever quarterly revenue at $ 204 Mn driven by differentiated portfolio. Gearing for the future with innovation driven initiatives in biosimilar and mRNA and putting digital at the centre of all that we do for our patients.